1020329-80-9

Basic information

• Product Name: ert-butyl 4-(bromomethylene)piperidine-1-carboxylate
• Synonyms: ert-butyl 4-(bromomethylene)piperidine-1-carboxylate;1-N-Boc-4-(bromomethylene)piperidine;Tert-Butyl4-(bromomethylene)piperidine-1-carboxylate;1-Boc-4-(BroMoMethylene)piperidine;4-Bromomethylene-piperidine-1-carboxylic acid tert-butyl ester;1-Boc-4-(Bromomethylene)
• CAS NO: 1020329-80-9
• Molecular Formula: C₁₁H₁₈BrNO₂
• Molecular Weight: 276.18
• Mol File: 1020329-80-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 317.686 °C at 760 mmHg
• Flash Point: 145.932 °C
• Appearance: /
• Density: 1.390
• Storage Temp.: 2-8°C
• PKA: -1.51±0.20(Predicted)
• CAS DataBase Reference: ert-butyl 4-(bromomethylene)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ert-butyl 4-(bromomethylene)piperidine-1-carboxylate(1020329-80-9)
• EPA Substance Registry System: ert-butyl 4-(bromomethylene)piperidine-1-carboxylate(1020329-80-9)

Safety Data

• Hazardous Substances Data: 1020329-80-9(Hazardous Substances Data)

Usage

General Description

Ert-butyl 4-(bromomethylene)piperidine-1-carboxylate is a chemical compound with the molecular formula C13H20BrNO2. It is a piperidine derivative that contains a bromomethylene functional group and a tert-butyl ester group. ert-butyl 4-(bromomethylene)piperidine-1-carboxylate is often used as a reagent in organic synthesis, particularly in the preparation of pharmaceuticals and other biologically active compounds. It is known for its ability to undergo nucleophilic substitution reactions, making it a valuable tool for chemists and researchers looking to introduce the piperidine moiety into their target molecules. Additionally, the tert-butyl ester group can provide protection to other functional groups during chemical reactions, making it a versatile building block for organic synthesis.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1034-49-7 (bromomethyl)triphenyl phosphonium bromide 
• 305794-65-4 tert-butyl 4-(dibromomethylidene)piperidine-1-carboxylate 

Downstream Products

• 1020329-87-6 tert-butyl 4-(3-hydroxybenzylidene)piperidine-1-carboxylate 
• 1020330-68-0 tert-butyl 4-(4-chloro-3-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)piperidine-1-carboxylate 
• 1020331-00-3 tert-butyl 4-(4-methyl-3-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)piperidine-1-carboxylate 
• 1020331-34-3 tert-butyl 4-(3-methyl-5-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)piperidine-1-carboxylate 
• 1020332-26-6 tert-butyl 4-(3-fluoro-5-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)piperidine-1-carboxylate 
• 1425972-75-3 tert-butyl 4-[4-(tetrahydro-2H-pyran-4-ylsulfonyl)benzylidene]piperidine-1-carboxylate 
• 1425970-50-8 tert-butyl 4-[2-chloro-4-(methoxycarbonyl)benzylidene]piperidine-1-carboxylate 
• 1191401-02-1 N-pyridazin-3-yl-4-[3-(tetrahydro-2H-pyran-2-ylmethoxy)benzylidene]piperidine-1-carboxamide 
• 1191400-42-6 N-pyridazin-3-yl-4-[3-(tetrahydrofuran-2-ylmethoxy)benzylidene]piperidine-1-carboxamide 
• 1107620-28-9 tert-Butyl 4-[3-(3,5-difluorophenyl)prop-2-ynylidene]piperidine-1-carboxylate 

Relevant articles and documents

SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5

Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula (I) or pharmaceutically acceptable salt thereof wherein ring A represents group A-I, A-II or A-III. Al represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A2 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A3 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A4 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A5 represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A6 represents -C(R4c)(R4c)- or -C(R4c)=; A7 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A8 represents -C(R4a)(R4a)-, -N(R4b)-, -O- or -S-; A9 represents -C(R4c)(R4c)- or -0-; A10 represents -C(R4c)(R4c)- or -0-; A11 represents -C(R4c)(R4c)- or -0-; A12 represents -C(R4a)(R4a)-, -O- or -S-; wherein group A-I, group A-II and group A-III de not contain adjacent oxygen atoms, adjacent oxygen and sulfur atoms or adjacent oxygen and nitrogen atoms or a moiety selected from the group consisting of N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S, wherein in each case the carbon atom in the N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S moiety is saturated; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a, R4b and R4c are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A- II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.